These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
836 related articles for article (PubMed ID: 32702598)
1. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens. Yao J; Li M; Zhang H; Ge Y; Weygant N; An G Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598 [TBL] [Abstract][Full Text] [Related]
2. The incidence and relative risk of PD-1/PD-L1 inhibitors-related colitis in non-small cell lung cancer: A meta-analysis of randomized controlled trials. Lin LL; Lin GF; Luo Q; Chen XQ Int Immunopharmacol; 2019 Dec; 77():105975. PubMed ID: 31704288 [TBL] [Abstract][Full Text] [Related]
3. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH Front Immunol; 2019; 10():108. PubMed ID: 30778352 [No Abstract] [Full Text] [Related]
4. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis. Xu M; Nie Y; Yang Y; Lu YT; Su Q Neurologist; 2019 May; 24(3):75-83. PubMed ID: 31045716 [TBL] [Abstract][Full Text] [Related]
5. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071 [TBL] [Abstract][Full Text] [Related]
6. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials. Shi Y; Duan J; Guan Q; Xue P; Zheng Y Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922 [TBL] [Abstract][Full Text] [Related]
7. Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis. Guo X; Li W; Hu J; Zhu EC; Su Q Eur J Clin Pharmacol; 2020 Oct; 76(10):1345-1354. PubMed ID: 32507925 [TBL] [Abstract][Full Text] [Related]
8. Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis. Hao W; Zhang J; Wang Y; Fang B; Jin S; Yuan J; Cai W Front Immunol; 2023; 14():1175809. PubMed ID: 37520574 [TBL] [Abstract][Full Text] [Related]
9. Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis. Hou YL; Wang DY; Hu JX; Tian RY; Wang W; Su Q; Li H; Wang YL Ocul Immunol Inflamm; 2022 Aug; 30(6):1449-1459. PubMed ID: 33970759 [TBL] [Abstract][Full Text] [Related]
10. Combination therapy with PD-1 or PD-L1 inhibitors for cancer. Hayashi H; Nakagawa K Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270 [TBL] [Abstract][Full Text] [Related]
11. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. Abu-Sbeih H; Tran CN; Ge PS; Bhutani MS; Alasadi M; Naing A; Jazaeri AA; Wang Y J Immunother Cancer; 2019 May; 7(1):118. PubMed ID: 31053161 [TBL] [Abstract][Full Text] [Related]
12. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Tian Y; Gao A; Wen Q; Wang S; Zhang S; Yang X; Su G; Sun Y Front Immunol; 2020; 11():595655. PubMed ID: 33391266 [TBL] [Abstract][Full Text] [Related]
13. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis. Zhou X; Yao Z; Bai H; Duan J; Wang Z; Wang X; Zhang X; Xu J; Fei K; Zhang Z; Tan F; Xue Q; Gao S; Gao Y; Wang J; He J Lancet Oncol; 2021 Sep; 22(9):1265-1274. PubMed ID: 34391508 [TBL] [Abstract][Full Text] [Related]
14. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Miyashita H; Mikami T; Satoi S; Cruz C; Galsky MD J Immunother; 2020; 43(9):291-298. PubMed ID: 32960847 [TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis. Liu M; Cheng X; Ni R; Zheng B; Huang S; Yang J Front Immunol; 2022; 13():1006860. PubMed ID: 36189211 [TBL] [Abstract][Full Text] [Related]
16. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials. Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874 [TBL] [Abstract][Full Text] [Related]
17. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials. Ge Y; Zhang H; Weygant N; Yao J Front Pharmacol; 2021; 12():640099. PubMed ID: 34447305 [No Abstract] [Full Text] [Related]
18. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis. Liu S; Gao W; Ning Y; Zou X; Zhang W; Zeng L; Liu J Front Immunol; 2022; 13():908173. PubMed ID: 35880172 [TBL] [Abstract][Full Text] [Related]
19. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials. Ma Z; Sun X; Zhang Y; Li H; Sun D; An Z; Zhang Y Thromb Haemost; 2022 Oct; 122(10):1757-1766. PubMed ID: 35772727 [TBL] [Abstract][Full Text] [Related]
20. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]